Catalog No.
DHF92406
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2a
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q02223 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, BCMA, PF-06863135, PF-3135, CAS: 2408850-14-4
Clone ID
Elranatamab
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States., PMID:40495704
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma., PMID:40491859
Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results., PMID:40384938
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial., PMID:40383818
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract., PMID:40345961
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system., PMID:40302414
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain., PMID:40193043
Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison., PMID:40190254
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047
Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review., PMID:40052837
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma., PMID:40000533
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database., PMID:39982395
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients., PMID:39955765
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754
Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab., PMID:39865264
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era., PMID:39809660
Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220
Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab., PMID:39744308
Practical insights into bispecific antibody therapy in multiple myeloma., PMID:39729045
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM., PMID:39695076
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006
Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection., PMID:39617677
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System., PMID:39458907
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma., PMID:39415515
B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice., PMID:39373355
[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]., PMID:39227195
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study., PMID:39055646
A tertiary care centre experience with Elranatamab: A report of three cases., PMID:38974232
Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy., PMID:38940040
Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis., PMID:38817306
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3., PMID:38794892
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma., PMID:38717927
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan., PMID:38687406
Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma., PMID:38546659
A pivotal decade for bispecific antibodies?, PMID:38465614
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study., PMID:38432433
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3., PMID:38420657
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma., PMID:38415370
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma., PMID:38347747
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms., PMID:38194680
Antibodies to watch in 2024., PMID:38178784
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma., PMID:38078866
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment., PMID:38004493
For research use only. Not for human or drug use.
